恩替卡韦治疗慢性乙型肝炎和乙型肝炎肝硬化96周疗效观察

目的探讨恩替卡韦治疗慢性乙型肝炎和乙型肝炎肝硬化96周的临床疗效。方法应用恩替卡韦治疗HBV DNA阳性的34例慢性乙型肝炎患者和24例乙型肝炎肝硬化患者,观察96周。结果 34例慢性乙型肝炎患者治疗12周、24周、48周和96周时HBV DNA低于检测下限比率分别为61.76%（21/34）,82.35%（28/34）,94.12%（32/34）和94.12%（32/34,P〈0.05）;22例乙型肝炎肝硬化患者也分别为72.73%（16/22）,81.82%（18/22）,81.82%（18/22）和90.91%（20/22,P〈0.05）;治疗期间未发生与应用恩替卡韦相关的不良反应。结论恩替卡韦治疗慢性乙型肝炎和乙型肝炎肝硬化患者有明显的疗效,安全性较好。

Efficacy of entecavir in the treatment of patients with chronic hepatitis B and cirrhosis

Objective To investigate the effectacy of entecavir in the treatment of patients with chronic hepatitis B and cirrhosis.Methods Thirty-four patients with chronic hepatitis B and twenty-four patients with HBV-induced liver cirrhosis took ETV 0.5mg/d orally for 96 weeks.Results In the CHB group,the rates of HBV DNA negativity at week 12,24,48 and 96 were 61.76%(21/34),82.35%(28/34),94.12%(32/34)and 94.12%(32/34,P<0.05),respectively;and in the LC group,they were 72.73%(16/22),81.82%(18/22),81.82%(18/22)and 90.91%(20/22,P<0.05),respectively;At week 12,the levels of serum ALT were significantly decreased(P<0.05).No side effect was observed in the patients during treatment.Conclusion ETV is effective and safe in treatment of patients with chronic hepatitis B and with HBV-induced liver cirrhosis.